IL22 and chronic obstructive pulmonary disease: Similarly, the magnitude of the reduction in sputum IL-22 levels was significant in patients with COPD treated with simvastatin compared with control subjects receiving placebo (mean difference, −48.6 pg/mL; 95% CI, −58.4 to −38.9; P < .001) (Fig 2B, Table 3).